

Information For the User
Sevelamer (800mg) Tablet

Sevmoxl C 800 Tablet

Sevmoxl C 800 Tablet

Composition:

Each film-coated tablet contains:

- **Sevelamer Carbonate IP** – 800 mg
- **Excipients** – q.s.
- **Colour:** Approved colour used

Dosage Form:

Tablet

Therapeutic Category:

Phosphate Binder

Pharmacology & Mechanism of Action:

Sevelamer is a non-absorbed phosphate-binding polymer that binds dietary phosphate in the gastrointestinal tract, reducing its absorption and thereby lowering serum phosphate levels. It does not contain calcium or metal, avoiding calcium load and metal toxicity. Sevelamer also binds bile acids and may help in lowering LDL cholesterol.

Indications:

- Hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis
- Phosphate control in end-stage renal disease (ESRD)

Dosage and Administration:

- Dosage should be individualized based on serum phosphate levels
- Usual starting dose: 800–1600 mg three times daily with meals
- Tablets should be swallowed whole with meals; do not crush, chew or split
- Serum phosphate should be monitored regularly, and dose adjusted accordingly

Contraindications:

- Hypersensitivity to Sevelamer or any component of the formulation
- Bowel obstruction
- Patients with severe gastrointestinal motility disorders

Warnings and Precautions:

- Use with caution in patients with dysphagia, swallowing disorders, severe constipation, or history of bowel obstruction
- May decrease absorption of fat-soluble vitamins and folic acid — supplementation may be

required

- Monitor serum bicarbonate and chloride levels during therapy
- Not recommended in pediatric patients unless prescribed

Drug Interactions:

- May reduce absorption of other oral medications – administer other drugs at least 1 hour before or 3 hours after Sevelamer
- Avoid simultaneous administration with ciprofloxacin, mycophenolate mofetil, levothyroxine, or cyclosporine without proper spacing
- May interfere with absorption of fat-soluble vitamins (A, D, E, K)

Adverse Effects:

- Common: Nausea, vomiting, diarrhea, flatulence, abdominal pain, dyspepsia
- Less common: Constipation, fecal impaction
- Rare: Intestinal obstruction, perforation, metabolic acidosis

Overdose:

- No specific antidote
- In case of overdose, symptomatic and supportive treatment is advised
- Monitor for gastrointestinal symptoms or obstruction

Storage:

Store below 25°C in a dry place
Protect from moisture and light
Keep out of reach of children

Manufactured in India for:



Cafoli Lifecare Pvt. Ltd.

(An ISO 9001: 2015 Certified Co.)

Plot no.: 367-FF, Industrial Area Phase-I,

Panchkula-134113

TM: Trademark Applied for